Simon Cooper
Chief Tech/Sci/R&D Officer bij MORPHIC HOLDING, INC.
Vermogen: - $ op 31-03-2024
Actieve functies van Simon Cooper
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MORPHIC HOLDING, INC. | Chief Tech/Sci/R&D Officer | 19-03-2024 | - |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 01-03-2024 | - |
Loopbaan van Simon Cooper
Eerdere bekende functies van Simon Cooper
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
KEROS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 02-08-2021 | 12-03-2024 |
KADMON HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 01-03-2021 | 01-07-2021 |
Anokion US, Inc. | Chief Tech/Sci/R&D Officer | 01-01-2019 | 01-02-2021 |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01-11-2012 | 01-07-2014 |
Sanofi SA | Corporate Officer/Principal | - | - |
Opleiding van Simon Cooper
Newcastle University Medical School | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 6 |
Zwitserland | 2 |
Frankrijk | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 5 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 7 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
KEROS THERAPEUTICS, INC. | Health Technology |
MORPHIC HOLDING, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
Sanofi SA | Health Technology |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Health Technology |
Anokion US, Inc. |
- Beurs
- Insiders
- Simon Cooper
- Ervaring